<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047229</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-011</org_study_id>
    <secondary_id>CDR0000257565</secondary_id>
    <secondary_id>NCI-5798</secondary_id>
    <nct_id>NCT00047229</nct_id>
  </id_info>
  <brief_title>Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)</brief_title>
  <official_title>A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of&#xD;
      doxorubicin by making tumor cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin&#xD;
      in treating patients who have locally advanced, recurrent, or metastatic hepatocellular&#xD;
      carcinoma (liver cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of oblimersen and doxorubicin in patients with&#xD;
           advanced hepatocellular carcinoma or other incurable solid tumor (closed to accrual as&#xD;
           of 11/7/03). (Phase I completed as of 1/16/04.)&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of objective response rate, in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the time to progression, response duration, progression-free survival, median&#xD;
           survival, and overall survival rates in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. (Phase I completed as of 1/16/04.)&#xD;
&#xD;
      Patients receive oblimersen IV continuously on days 1-7 and doxorubicin IV over 5 minutes on&#xD;
      day 5. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of oblimersen and doxorubicin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, additional patients*, including 6 patients with hepatocellular carcinoma (HCC),&#xD;
      are treated at the recommended phase II dose. (Phase I completed as of 1/16/04.)&#xD;
&#xD;
      NOTE: *Other solid tumors closed to accrual as of 11/7/03; only accruing HCC patients&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this&#xD;
      study within 6 months (phase I completed as of 1/16/04). A total of 30 patients will be&#xD;
      accrued for the phase II portion of this study within 10-15 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of objective response (complete and partial)</measure>
    <time_frame>Up to 280 days</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Objective response rate of &gt;= 30% is considered active, and &lt;10% is considered inactive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable disease rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC)&#xD;
&#xD;
                    -  Locally advanced, recurrent, or metastatic&#xD;
&#xD;
                    -  Not candidates for surgical/radical therapies&#xD;
&#xD;
               -  Other solid tumor that is incurable (closed to accrual as of 11/7/03)&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Target lesion may not be in a previously irradiated field unless subsequent&#xD;
                  progression was documented&#xD;
&#xD;
          -  No ascites&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST no greater than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin greater than 3.5 g/dL&#xD;
&#xD;
          -  No cirrhosis worse than Childs-Pugh class A&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF normal by MUGA&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Good nutritional status&#xD;
&#xD;
          -  No encephalopathy&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No prior allergic reactions to compounds of similar chemical or biological composition&#xD;
             to oblimersen or doxorubicin&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No more than 1 prior biologic therapy regimen for patients with HCC&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Patients with HCC:&#xD;
&#xD;
               -  No prior systemic chemotherapy&#xD;
&#xD;
               -  Prior chemotherapy as part of localized chemoembolization therapy may be allowed&#xD;
                  (no more than 150 mg/m^2 for doxorubicin) if completed at least 8 weeks before&#xD;
                  study treatment&#xD;
&#xD;
          -  All other patients (closed to accrual as of 11/7/03):&#xD;
&#xD;
               -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
               -  No prior doxorubicin, epirubicin, or other anthracycline&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No more than 3,000 cGy to fields including substantial bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 8 weeks since prior surgery&#xD;
&#xD;
          -  Prior liver transplant for HCC allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 8 weeks since other locally ablative therapies&#xD;
&#xD;
          -  No concurrent commercial or other investigational agents or therapies&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Knox, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT00047229</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <results_reference>
    <citation>Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. Epub 2007 Dec 4.</citation>
    <PMID>18060598</PMID>
  </results_reference>
  <results_reference>
    <citation>Knox JJ, Chen E, Feld R, et al.: A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. [Abstract] J Clin Oncol 24 (Suppl 18): A-14072, 2006.</citation>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

